BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Young LK, Matthew SZ, Houston JG. Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals. Eur Radiol 2019;29:1922-30. [PMID: 30276674 DOI: 10.1007/s00330-018-5737-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Ian Paterson D, White JA, Butler CR, Connelly KA, Guerra PG, Hill MD, James MT, Kirpalani A, Lydell CP, Roifman I, Sarak B, Sterns LD, Verma A, Wan D, Crean AM, Grosse-Wortmann L, Hanneman K, Leipsic J, Manlucu J, Nguyen ET, Sandhu RK, Villemaire C, Wald RM, Windram J; Primary Panel., Secondary Panel. 2021 Update on Safety of Magnetic Resonance Imaging: Joint Statement From Canadian Cardiovascular Society/Canadian Society for Cardiovascular Magnetic Resonance/Canadian Heart Rhythm Society. Can J Cardiol 2021;37:835-47. [PMID: 34154798 DOI: 10.1016/j.cjca.2021.02.012] [Reference Citation Analysis]
2 Strimaite M, Harman CLG, Duan H, Wang Y, Davies GL, Williams GR. Layered terbium hydroxides for simultaneous drug delivery and imaging. Dalton Trans 2021;50:10275-90. [PMID: 34254077 DOI: 10.1039/d1dt01251g] [Reference Citation Analysis]
3 Labiste CC, McElroy E, Subhawong TK, Banks JS. Systematic review: investigating the added diagnostic value of gadolinium contrast agents for osteomyelitis in the appendicular skeleton. Skeletal Radiol 2021. [PMID: 34643771 DOI: 10.1007/s00256-021-03915-4] [Reference Citation Analysis]
4 Lunyera J, Mohottige D, Alexopoulos AS, Campbell H, Cameron CB, Sagalla N, Amrhein TJ, Crowley MJ, Dietch JR, Gordon AM, Kosinski AS, Cantrell S, Williams JW Jr, Gierisch JM, Ear B, Goldstein KM. Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review. Ann Intern Med 2020;173:110-9. [PMID: 32568573 DOI: 10.7326/M20-0299] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Mallio CA, Rovira À, Parizel PM, Quattrocchi CC. Exposure to gadolinium and neurotoxicity: current status of preclinical and clinical studies. Neuroradiology 2020;62:925-34. [DOI: 10.1007/s00234-020-02434-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
6 Hicks CW, Clark TWI, Cooper CJ, de Bhailis ÁM, De Carlo M, Green D, Małyszko J, Miglinas M, Textor SC, Herzog CA, Johansen KL, Reinecke H, Kalra PA. Artherosclerotic Renovascular Disease: A KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. Am J Kidney Dis 2021:S0272-6386(21)00776-9. [PMID: 34384806 DOI: 10.1053/j.ajkd.2021.06.025] [Reference Citation Analysis]
7 Rodríguez-Rodríguez A, Shuvaev S, Rotile N, Jones CM, Probst CK, Dos Santos Ferreira D, Graham-O Regan K, Boros E, Knipe RS, Griffith JW, Tager AM, Bogdanov A Jr, Caravan P. Peroxidase Sensitive Amplifiable Probe for Molecular Magnetic Resonance Imaging of Pulmonary Inflammation. ACS Sens 2019;4:2412-9. [PMID: 31397156 DOI: 10.1021/acssensors.9b01010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
8 Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. Am J Kidney Dis 2021;77:517-28. [PMID: 32861792 DOI: 10.1053/j.ajkd.2020.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Braun J, Busse R, Darmon-Kern E, Heine O, Auer J, Meyl T, Maurer M, Hamm B, de Bucourt M. Baseline characteristics, diagnostic efficacy, and peri-examinational safety of IV gadoteric acid MRI in 148,489 patients. Acta Radiol 2020;61:910-20. [PMID: 31739672 DOI: 10.1177/0284185119883390] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Krestan C. [Contrast media - Guidelines for practical use]. Radiologe 2019;59:444-53. [PMID: 31025046 DOI: 10.1007/s00117-019-0523-8] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Lancelot E, Raynaud J, Desché P. Current and Future MR Contrast Agents: Seeking a Better Chemical Stability and Relaxivity for Optimal Safety and Efficacy. Invest Radiol 2020;55:578-88. [DOI: 10.1097/rli.0000000000000684] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
12 Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis. JAMA Intern Med 2020;180:223-30. [PMID: 31816007 DOI: 10.1001/jamainternmed.2019.5284] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 31.0] [Reference Citation Analysis]
13 Panich AM, Salti M, Prager O, Swissa E, Kulvelis YV, Yudina EB, Aleksenskii AE, Goren SD, Vul' AY, Shames AI. PVP-coated Gd-grafted nanodiamonds as a novel and potentially safer contrast agent for in vivo MRI. Magn Reson Med 2021;86:935-42. [PMID: 33724543 DOI: 10.1002/mrm.28762] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Petronek MS, Steinbach EJ, Kalen AL, Builta ZJ, Callaghan CM, Hyer DE, Spitz DR, Flynn RT, Buatti JM, Magnotta VA, Zepeda-Orozco D, St-Aubin JJ, Allen BG. Assessment of Gadobutrol Safety in Combination with Ionizing Radiation Using a Preclinical MRI-Guided Radiotherapy Model. Radiat Res 2021;195:230-4. [PMID: 33347596 DOI: 10.1667/RADE-20-00199.1] [Reference Citation Analysis]